158. Tuberous sclerosis
100 clinical trials,   62 drugs   (DrugBank: 16 drugs),   35 drug target genes,   115 drug target pathways
Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04285346 (ClinicalTrials.gov) | April 8, 2020 | 18/2/2020 | Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) | A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B) | Tuberous Sclerosis | Drug: Ganaxolone | Marinus Pharmaceuticals | NULL | Recruiting | 2 Years | 65 Years | All | 30 | Phase 2 | United States |